b001
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Mar 22, 2018 (NCT03332121)
Timeline
Indications
Mechanism of action
EGFR inhibitor
TNFSF4 inhibitor
ERBB3 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06413654 | Phase 2/Phase 3 (Phase 3) | Jul 17, 2024 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05145361 | Early Phase 1 (Phase 1) | Jan 15, 2022 | Shanghai Pharmaceuticals Holding Co., Ltd, Tianjin Medical University |
| NCT03332121 | Phase 1 | Mar 22, 2018 | Shanghai Pharmaceuticals Holding Co., Ltd, Tsinghua University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Pharmaceuticals Holding Co., Ltd | For profit | 3 | 3 | 2 | 2018 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Tsinghua University | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1